Monotherapy vs doublet chemotherapy vs Folfirinox: who and why

Monotherapy vs doublet chemotherapy vs Folfirinox: who and why

Authors

  • Evaristo Maiello Oncology Unit, Dpt of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG)
  • Paolo Petreni Medical Oncology Unit, Dpt of Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
  • Elisa Giommoni Medical Oncology Unit, Dpt of Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
  • Luciano Nanni Oncology Unit, Dpt of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG)
  • Tiziana Pia Latiano Oncology Unit, Dpt of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG)
  • Francesco Di Costanzo Medical Oncology Unit, Dpt of Oncology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy

Downloads

Published

2014-03-01

How to Cite

1.
Maiello E, Petreni P, Giommoni E, Nanni L, Latiano TP, Di Costanzo F. Monotherapy vs doublet chemotherapy vs Folfirinox: who and why. Eur J Oncol Env Hea [Internet]. 2014 Mar. 1 [cited 2025 Apr. 6];19(1S):47-9. Available from: https://mattioli1885journals.com/index.php/EJOEH/article/view/4264

Most read articles by the same author(s)